ClinicalTrials.gg
CompletedNCT00980447Updated Feb 8, 2010

Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

A Phase 2 interventional study of UMN-0501 and UMN-0501 in Influenza and Virus Diseases, sponsored by UMN Pharma Inc.. Completed at 2 sites in Japan. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-02-08.

Sponsored by UMN Pharma Inc. (part of Shionogi) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing FluBlok in Influenza, Human — none open to participants now, none under way, none of them phase 3. FluBlok · Influenza, Human.

Enrollment
10th of 11
90 · median 606
Started
2009
the only one that year
Phase 2
2 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
2 of 11
UMN Pharma Inc.

Among the 11 studies testing FluBlok in Influenza, Human, this one is the 10th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 2, and was the 4th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

None of the 11 studies testing FluBlok in Influenza, Human is open now. The open studies under Influenza, Human, anywhere →

Where they have run

About FluBlok

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing FluBlok in Influenza, Human as a file.
02

Study summary

UMN-0501 is a purified recombinant influenza HA vaccine (A H5N1/Vietnam/1203/2004).

The purpose of the present study is to evaluate immunogenicity, safety and optimal dose among three different doses of UMN-0501 following two same-dose vaccinations of UMN-0501 per patient with a 3 week interval between vaccination in healthy young adults.

Immunogenicity will be confirmed by both microneutralization (MN) antibody and hemagglutination inhibition (HAI) titer levels in the serums of subjects after receiving different doses of UMN-0501. There will be three dose groups with 30 subjects per group for a total of 90 healthy young adults aged 20-40 years enrolled in this study.

03

Conditions studied

  • Influenza
  • Virus Diseases

Keywords

  • H5N1
  • Vaccine
  • Influenza H5N1
  • Avian influenza H5N1
  • Pandemic
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult as determined by medical history, physical examination, laboratory test, and clinical judgment of the investigator.
  • Males and females aged 20-40 years.
  • Provides signed form after received a detailed explanation of the study protocol prior to any study procedures.

Exclusion criteria

Exclusion Criteria:

  • (BMI) 30 kg/m2 and above.
  • Has a history of a A/H5N1 influenza virus infection and subjects had received other A/H5N1 influenza vaccine.
  • Has a history of allergic reaction by food and medicine including vaccine, and acute fever illness (greater than 39.0C) within 2 days of vaccination.
  • Has a history of Guillain-Barre syndrome or acute disseminated encephalomyelitis (ADEM).
  • Has severe allergic diseases.
  • Has asthma.
  • Has a history of convulsions.
  • Has a history of any serious disease.
  • Known impairment of imune function.
  • Known rheumatism and disease.
  • Receipt of medicines that would affect evaluation of immunogenicity.
  • Receipt of any or receipt of any inactivated vaccine/toxoid prior to enrollment.
  • Blood donation prior to enrollment.
  • Receipt of another investigation agent prior to enrollment.
  • History of alcohol or drug abuse.
  • Females who are pregnant or potentially childbearing or are breastfeeding.
  • Ineligible subject based on the judgement of the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    UMN-0501 45µg

    Recombinant H5N1 vaccine 45µg

    Biological: UMN-0501

  • Experimental
    UMN-0501 90µg

    Recombinant H5N1 vaccine 90µg

    Biological: UMN-0501

  • Experimental
    UMN-0501 135µg

    Recombinant H5N1 vaccine 135µg

    Biological: UMN-0501

Interventions

  • BiologicalUMN-0501

    2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart

    Also known as: UMN-05

  • BiologicalUMN-0501

    2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart

    Also known as: UMN-05

  • BiologicalUMN-0501

    2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart

    Also known as: UMN-05

06

What researchers measure

Primary outcomes

  1. Number of subjects who achieve seroconversion, seroprotection, GMTs and GMT ratio to baseline, 21 days after the 2nd vaccination defined by serum neutralizing and HAI titers against the influenza H5N1 A/Vietnam/1203/2004 virus.

    Time frame: Day 42: 21 days after 2nd vaccination (42 days after 1st vaccination)

  2. Frequencies of AEs including vaccine-related reactogenicity events.

    Time frame: Throughout study period: Day0 to 42

Secondary outcomes

  1. To explore T-cell response in the subset of subjects after each vaccination as determined by proliferation and cytokine production capacity of T-cells re-stimulate by H5N1 A/Vietnam/1203/2004 recombinant virus antigens.

    Time frame: Day0, Day 21 and Day 42

07

Study locations

2 sites
  • National Hospital Organization Osaka Minami Medical Center
    Kawachinagano City, Osaka 586-8521, Japan
  • National Hospital Organization Tokyo Medical Center
    Meguro-ku, Tokyo 152-8902, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2009
First posted
Sep 21, 2009
Start
Oct 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Last update
Feb 8, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00980447
Lead sponsor
UMN Pharma Inc.
First posted
Sep 21, 2009
Start date
Oct 2009
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Feb 8, 2010

Study contacts

Tetsuo Nakayama, MD, PhD
study director · Kitasato University Kitasato Institute for Life Sciences
Suminobu Ito, MD, PhD
principal investigator · National Hospital Organization

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluBlok

Start the discussion